Clinical trial
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892
Study timeline
Study start (actual)2024-05-20Date precision: day
Registry last updated2026-07-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Neoplasmsunresolved
Gastroesophageal Junction Adenocarcinomaunresolved
HER2 Low Breast Neoplasmsunresolved
HER2 Positive Breast Neoplasmsunresolved
Stomach Neoplasmsunresolved
Triple Negative Breast Neoplasmsunresolved
Metastatic Breast Cancerunresolved
Metastatic Gastric Cancerunresolved
Advanced Breast Cancerunresolved
Advanced Gastric Cancerunresolved
Interventions
tucatinibDRUG · verified · RxNorm: tucatinib
Sponsors & collaborators
Seagen, a wholly owned subsidiary of Pfizerlead sponsor
RemeGen Co., Ltd.collaborator
Mapped research locations
AtlantaGeorgia, United States5TucsonArizona, United States5St LouisMissouri, United States4LondonUnited Kingdom4TampaFlorida, United States4BostonMassachusetts, United States3NashvilleTennessee, United States3BarcelonaSpain3SeattleWashington, United States3TaipeiTaiwan3New YorkNew York, United States2TorontoOntario, Canada2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06157892 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.